Empagliflozin

Empagliflozin is a potent, highly selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2) that has transformed the management of metabolic and cardiorenal diseases [label]. By blocking glucose reabsorption in the proximal convoluted tubule, it lowers the renal threshold for glucose and promotes osmotic diuresis and natriuresis [label]. This mechanism provides a unique, insulin-independent pathway for glycemic control while simultaneously exerting profound protective effects on the heart and kidneys ^[6]A1b[7]A1a. Empagliflozin represents a therapeutic shift from simple glucose-lowering to comprehensive organ protection, significantly reducing the risk of cardiovascular death and heart failure hospitalizations across a broad spectrum of patients ^[1]A1a[4]A1b.

Also Called / Synonyms:

• Jardiance
• BI 10773
• SGLT2 inhibitor (SGLT2i)
• Gliflozin

Chemical Identity and Composition

Empagliflozin is a C-glycoside derivative with the chemical name D-Glucitol,1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-, (1S) [label]. It possesses a molecular formula of C23H27ClO7 and a molecular weight of 450.91 g/mol [label]. As a white to yellowish, non-hygroscopic powder, the drug exhibits poor solubility in water but is soluble in 50% acetonitrile/water [label]. Commercial formulations are available as 10 mg and 25 mg film-coated tablets, which include inactive ingredients such as colloidal silicon dioxide, croscarmellose sodium, and lactose monohydrate to ensure stability [label].

Clinical Scope and Indications

The clinical utility of empagliflozin extends beyond glycemic management to include the reduction of major adverse cardiovascular events (MACE) and the slowing of chronic kidney disease (CKD) progression ^[5]D5[7]A1a. It is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults, regardless of ejection fraction [label]. Furthermore, it is approved to mitigate the risk of sustained eGFR decline, ESKD, and cardiovascular death in patients with CKD at risk of progression [label]. While it serves as an adjunct to diet and exercise for type 2 diabetes in patients ≥10 years old, it is not recommended for type 1 diabetes due to the risk of diabetic ketoacidosis [label].

Terminology and Definitions

• eGFR: Estimated glomerular filtration rate; a measure of kidney function. Empagliflozin is likely ineffective for glycemic control when eGFR is <30 mL/min/1.73 m² [label].
• ESKD: End-stage kidney disease; the stage of kidney failure requiring dialysis or transplantation [label].
• UACR: Urine albumin-to-creatinine ratio; a clinical marker used to assess the severity of albuminuria in CKD ^[5]D5.

Selective inhibition of the sodium-glucose cotransporter 2 (SGLT2) in the proximal convoluted tubule serves as the primary pharmacological action of this agent [label]. SGLT2 is the predominant transporter responsible for reabsorbing approximately 90% of filtered glucose from the glomerular filtrate back into the systemic circulation [label]. By blocking this pathway, the drug lowers the renal threshold for glucose and induces significant urinary glucose excretion (UGE) [label]. In patients with type 2 diabetes, this mechanism results in the loss of approximately 64 g to 78 g of glucose per day, effectively lowering plasma glucose levels independently of insulin secretion or sensitivity [label].

Hemodynamic and Renal Effects

Beyond glycemic control, the inhibition of sodium reabsorption in the proximal tubule increases sodium delivery to the distal tubule and the macula densa [label]. This restoration of tubuloglomerular feedback triggers afferent arteriolar vasoconstriction, which reduces intraglomerular pressure and mitigates hyperfiltration-mediated injury [label, 13]. These hemodynamic shifts extend to the cardiovascular system, where reduced sodium retention and osmotic diuresis lower both cardiac preload and afterload [label]. Furthermore, the drug appears to downregulate sympathetic nervous system activity and reduce systemic blood pressure without inducing compensatory tachycardia [label, 11].

Metabolic and Cellular Cardioprotection

Cardioprotection is mediated through the activation of metabolic sensing pathways, specifically AMP-activated protein kinase (AMPK) and liver kinase B1 (LKB1) ^{[10]D5[12]D5[17]D5}. Activation of the AMPK/mTORC1 pathway enhances autophagy, a critical cellular process that maintains cardiomyocyte proteostasis and mitochondrial health ^[16]D5[17]D5. The drug also modulates myocardial energy metabolism by shifting fuel utilization and increasing glutathione-mediated redox defenses, which mitigates oxidative stress and improves myocardial efficiency in the context of heart failure ^{[9]D5[16]D5[20]C4}.

Inhibition of Programmed Cell Death

Advanced molecular signaling involves the NRF2 (nuclear factor erythroid 2-related factor 2) pathway, which protects against ferroptosis—an iron-dependent form of regulated cell death ^[14]D5[18]D5. By upregulating glutathione peroxidase 4 (GPX4) and stabilizing lysosomal iron homeostasis through the ACC-NRF2-TFEB axis, the drug prevents cardiomyocyte loss in diabetic cardiomyopathy ^[14]D5[18]D5. Additionally, it suppresses pyroptosis in renal tubular cells by inhibiting SGK1-mediated signaling, providing a multi-layered defense against inflammatory tissue injury and fibrosis ^[13]D5. Emerging evidence also suggests potential neuroprotective effects, with real-world data indicating a reduced risk of Alzheimer's disease (HR ≤ 0.67) compared to other antidiabetic agents ^[15]B3b.

Peak plasma concentrations occur approximately 1.5 hours after oral administration, reflecting rapid systemic absorption [label]. While a high-fat, high-calorie meal reduces the maximum plasma concentration ($C_{max}$) by 37% and the area under the curve (AUC) by 16%, these changes are not clinically significant; therefore, the medication may be administered with or without food [label, 28]. Systemic exposure increases in a dose-proportional manner across the therapeutic range of 10 mg to 25 mg [label, 26]. Steady-state concentrations are typically reached within five days of once-daily dosing, with minimal accumulation (~22%) observed [label].

Distribution and Protein Binding

The apparent steady-state volume of distribution is estimated at 73.8 L, suggesting extensive tissue distribution [label]. The drug exhibits a plasma protein binding rate of 86.2%, primarily to albumin , and shows a red blood cell partitioning of approximately 36.8% [label]. These distribution characteristics remain consistent across different ethnic populations, including healthy Japanese and Chinese subjects ^{[26]A1b[30]A1b}.

Metabolism and Elimination

Glucuronidation via uridine 5'-diphospho-glucuronosyltransferases (UGT2B7, UGT1A3, UGT1A8, and UGT1A9) represents the primary metabolic pathway [label]. No major metabolites (defined as >10% of total drug-related material) are detectable in human plasma; the most abundant are three glucuronide conjugates, each accounting for less than 10% of systemic exposure [label].

The terminal elimination half-life is approximately 12.4 hours, supporting a once-daily dosing interval [label]. Following administration of an oral [14C]-labeled dose, approximately 95.6% of the radioactivity is recovered, with 54.4% eliminated in the urine and 41.2% in the feces [label]. Most of the drug excreted in the feces is unchanged parent drug, while the majority in the urine is excreted as glucuronide metabolites [label].

Impact of Renal and Hepatic Impairment

Renal function significantly alters the relationship between systemic exposure and clinical efficacy. As the glomerular filtration rate (eGFR) declines, systemic exposure (AUC) increases, yet the pharmacodynamic effect—urinary glucose excretion—decreases because the drug's site of action is the tubular lumen ^[25]B2b. In patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), AUC increases by 66% compared to those with normal function ^[25]B2b.

Hepatic impairment also increases systemic exposure, likely due to reduced first-pass metabolism or altered protein binding. AUC increases by approximately 23%, 47%, and 48% in patients with mild, moderate, and severe hepatic impairment ( Child-Pugh A, B, and C), respectively ^[24]B2b. Despite these increases, the changes are not considered large enough to warrant routine dose adjustments in patients with liver disease ^[24]B2b.

Hemodynamic Effects on Kidney Function

Initiation of therapy typically results in an acute, transient "dip" in eGFR of 2–4 mL/min/1.73 m² within the first four weeks ^[53]A1b. This phenomenon is hemodynamic rather than toxic, resulting from reduced intraglomerular pressure via restored tubuloglomerular feedback ^[53]A1b. Slope analyses from the EMPA-REG OUTCOME trial demonstrate that after this initial dip, the rate of chronic eGFR decline is significantly slower compared to placebo (-0.23 vs -1.46 mL/min/1.73 m²/year), and the effect is reversible upon drug discontinuation ^[53]A1b.

Urinary glucose excretion (UGE) increases immediately following the first dose, driven by a reduction in the renal threshold for glucose reabsorption [label]. In patients with type 2 diabetes, 10 mg and 25 mg doses result in mean UGE of 64 g/day and 78 g/day, respectively [label]. This effect is maintained over chronic treatment but returns to baseline within 3 days of drug cessation [label].

Renal Hemodynamics and eGFR Slopes

Initiation triggers a characteristic hemodynamic shift in the kidney, manifesting as an acute, reversible "dip" in eGFR ^[53]A1b. This occurs because SGLT2 inhibition increases sodium delivery to the distal tubule, which activates tubuloglomerular feedback and induces afferent arteriolar vasoconstriction [label]. In the EMPA-REG OUTCOME trial, this initial decline averaged 2–4 mL/min/1.73 m² within the first 4 weeks ^[53]A1b. While initially concerning to clinicians, this reduction reflects a protective decrease in intraglomerular pressure rather than structural injury [label]^[53]A1b. Long-term maintenance treatment subsequently stabilizes the eGFR slope at -0.23 mL/min/1.73 m²/year, significantly preserving renal function compared to the -1.46 mL/min/1.73 m²/year decline observed with placebo ^[53]A1b.

Systemic and Metabolic Effects

Beyond glycemic control, the drug induces a modest natriuresis and osmotic diuresis . Mean 24-hour urine volume increases by 341 mL on the first day of 25 mg therapy, though this effect attenuates to 135 mL by day five as compensatory mechanisms engage [label]. Systemically, SGLT2 inhibition shifts the insulin-to-glucagon ratio, which may increase circulating ketone bodies, particularly during fasting states ^[65]A1a. No clinically significant effect on the QTc interval is observed, even at supratherapeutic doses of 200 mg [label].

Emerging evidence suggests secondary pharmacodynamic benefits in metabolic dysfunction-associated steatotic liver disease ( MASLD ), where treatment reduces alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels alongside hepatic steatosis ^[33]A1a. These effects complement the primary reductions in HbA1c, body weight, and blood pressure observed across phase III trials ^{[65]A1a[37]A1b}.

Therapeutic utility extends across the metabolic, cardiovascular, and renal continuums, positioning the agent as a foundational therapy for multi-organ protection. Clinical application is primarily driven by its ability to decouple glycemic control from systemic organ preservation, particularly in patients with high cardiovascular or renal risk profiles.

Glycemic Control in Type 2 Diabetes

Management of type 2 diabetes mellitus (T2DM) involves use as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older [label]. In monotherapy trials, doses of 10 mg and 25 mg achieved statistically significant placebo-adjusted HbA1c reductions of 0.7% and 0.9%, respectively, at 24 weeks [label]. Beyond monotherapy, it is frequently utilized as an add-on to metformin or in fixed-dose combinations with DPP-4 inhibitors like sitagliptin, where it provides superior HbA1c lowering and weight reduction compared to placebo ^{[35]A1b[37]A1b}. However, it is not recommended for glycemic control in patients with an eGFR <30 mL/min/1.73 m² because its glucose-lowering efficacy is dependent on glomerular filtration [label].

Cardiovascular Risk and Heart Failure

Reduction of cardiovascular (CV) death is a primary indication for adults with T2DM and established cardiovascular disease [label]. In the broader heart failure (HF) population, it is indicated to reduce the risk of CV death and hospitalization for heart failure (HHF) regardless of left ventricular ejection fraction [label]. Meta-analyses confirm that these benefits extend to all-cause mortality and all-cause hospitalization in patients with both HF and T2DM ^[43]A1a. Early initiation following acute myocardial infarction is also under investigation for its potential to modulate NLRP3 inflammasome activity and reduce early recurrent CV risk ^[46]B2b.

Chronic Kidney Disease (CKD)

Preservation of renal function is a core clinical objective in adults with CKD at risk of progression [label]. Treatment reduces the risk of sustained eGFR decline, end-stage kidney disease (ESKD), and CV death [label]. Clinical use is characterized by an initial, reversible hemodynamic "dip" in eGFR of approximately 2–4 mL/min/1.73 m² within the first 4 weeks, followed by long-term stabilization of kidney function ^[53]A1b. Long-term slope analysis shows an annual eGFR decline of only -0.23 mL/min/1.73 m² with treatment compared to -1.46 mL/min/1.73 m² with placebo ^[53]A1b.

Emerging and Off-Label Uses

Clinical evidence supports several emerging applications beyond standard metabolic indications. It is being evaluated for mitigating weight gain and metabolic derangements in patients with schizophrenia treated with atypical antipsychotics ^[44]A1b. Additionally, it may reduce the risk of hyperkalemia in high-risk CKD patients when used in combination with mineralocorticoid receptor antagonists like finerenone ^[50]B2b.

Standard administration involves a 10 mg oral dose once daily in the morning, taken with or without food [label]. While this 10 mg dose is the fixed therapeutic target for reducing cardiovascular death and hospitalizations in heart failure or slowing progression in chronic kidney disease (CKD), the regimen for glycemic control in Type 2 diabetes mellitus (T2DM) allows for titration [label]. In adults and pediatric patients aged 10 years and older with T2DM, clinicians may increase the dose to 25 mg once daily if the 10 mg dose is well-tolerated but additional glycemic control is required [label].

Pre-initiation Screening and Renal Thresholds

Assessment of renal function via estimated glomerular filtration rate (eGFR) and volume status is mandatory prior to the first dose [label]. In patients with evidence of volume depletion, clinicians must correct this condition before initiating therapy to mitigate the risk of acute kidney injury [label]. For the specific indication of glycemic control, initiation is not recommended if the eGFR is below 30 mL/min/1.73 m² [label]. However, in patients already established on the medication for CKD or heart failure, the 10 mg dose is typically maintained even as eGFR fluctuates, provided the benefits outweigh the risks [label].

Initiation of therapy is associated with an acute, transient dip in eGFR—approximately 2–4 mL/min/1.73 m²—within the first four weeks ^[53]A1b. This hemodynamic shift reflects a reduction in intraglomerular pressure rather than structural damage; landmark slope analyses from the EMPA-REG OUTCOME trial demonstrate that after this initial decline, the annual rate of eGFR loss is significantly slower compared to placebo (-0.23 vs -1.46 mL/min/1.73 m²/year, p<0.001) ^[53]A1b.

Surgical Interruption and Missed Doses

Therapy must be withheld for at least 3 days prior to major surgery or any procedure requiring prolonged fasting [label]. This precaution reduces the risk of SGLT2 inhibitor-associated diabetic ketoacidosis (DKA), which can occur even with near-normal blood glucose levels [label]. Treatment should only resume once the patient is hemodynamically stable and has resumed normal oral intake [label].

If a dose is missed, patients should take it as soon as they remember, but they must not double the dose to make up for a missed one [label]. In acute clinical scenarios such as myocardial infarction, early initiation (at discharge) has been studied to modulate inflammatory markers like the NLRP3 inflammasome, though the standard 10 mg daily dose remains the clinical benchmark ^[46]B2b.

Special Populations

Use during the second and third trimesters of pregnancy is not recommended, as animal models have demonstrated reversible renal pelvic and tubule dilatations at exposures 13 times the maximum human dose [label]. Because human kidney maturation continues through the first two years of life, the drug is also contraindicated during lactation due to the potential for serious adverse effects on postnatal renal development [label]. In pediatric patients (10–17 years), the pharmacokinetic profile is largely consistent with adults, though the area under the curve (AUC) may be slightly lower in adolescents compared to adults at the 10 mg dose level ^{[27]B2b[57]A1b}.

Renal function serves as the primary determinant for dose adjustments and therapeutic viability [label]. While empagliflozin provides cardiovascular and renal protection down to lower eGFR levels, it is not recommended for glycemic control in patients with an eGFR < 30 mL/min/1.73 m² due to diminished glucose-lowering efficacy [label]. Clinicians must assess renal function prior to initiation and monitor periodically thereafter [label]. An acute, transient decline in eGFR (typically 2–4 mL/min/1.73 m²) often occurs within the first 4 weeks of therapy, reflecting a reduction in intraglomerular pressure ^[53]A1b. This "dip" is hemodynamically mediated, consistent across chronic kidney disease risk subgroups, and generally reverses upon drug cessation, returning toward baseline levels ^[53]A1b.

Volume status requires careful assessment and correction before starting therapy, particularly in patients with an eGFR < 60 mL/min/1.73 m², the elderly (≥75 years), or those on loop diuretics [label]. These populations face an increased risk of symptomatic hypotension and acute kidney injury [label]. In a pooled analysis of over 15,000 patient-years, the incidence of volume depletion events was higher in patients aged 75 years or older (3.0–3.2 per 100 patient-years) compared to placebo (2.3 per 100 patient-years) ^[65]A1a. To mitigate the risk of euglycemic diabetic ketoacidosis , empagliflozin must be withheld for at least 3 days prior to major surgery or procedures involving prolonged fasting [label]. Therapy should only resume once the patient is clinically stable and has resumed oral intake [label].

Standard titration for glycemic control in adults and pediatric patients aged 10 years and older begins at 10 mg once daily [label]^[57]A1b. If additional glycemic control is required and the initial dose is well tolerated, the dosage may be increased to 25 mg once daily [label]^[61]A1b. When used as an adjunct to insulin or insulin secretagogues, a lower dose of the background medication may be required to reduce the risk of hypoglycemia [label]^[65]A1a. If a dose is missed, patients should take it as soon as possible but must not double the next dose [label].

Genital mycotic infections occur in 5.4% to 6.4% of women treated with empagliflozin, representing the most frequent adverse reaction observed in clinical trials [label]. These infections, which include vulvovaginal candidiasis and mycotic vulvovaginitis, are significantly more common than in placebo groups (1.5%) and are driven by the drug's primary mechanism of increasing urinary glucose concentration [label], ^[65]A1a. In men, the incidence is lower but still elevated compared to placebo, ranging from 1.6% to 3.1% [label]. Pooled safety data from over 15,000 patient-years confirm that while genital infections are increased, the overall incidence of urinary tract infections (UTIs) remains comparable to placebo, at approximately 8.7 to 9.5 events per 100 patient-years ^[65]A1a.

Hemodynamic and Renal Effects

Initiation of therapy typically triggers an acute, reversible reduction in the estimated glomerular filtration rate (eGFR) of 2–4 mL/min/1.73 m² within the first four weeks ^[53]A1b. This "eGFR dip" reflects a hemodynamic reduction in intraglomerular pressure rather than structural tubular injury ^[53]A1b. In the EMPA-REG OUTCOME trial, the adjusted mean eGFR slope decreased by 0.77 mL/min/1.73 m² per week during the first month, whereas the chronic maintenance phase showed long-term preservation of kidney function with an annual decline of only 0.23 mL/min/1.73 m² compared to 1.46 mL/min/1.73 m² in the placebo group (P < 0.001) ^[53]A1b. Upon drug cessation, eGFR typically returns toward baseline levels, confirming the functional nature of the initial decline ^[53]A1b.

Metabolic and Systemic Risks

Diabetic ketoacidosis (DKA) is a rare but life-threatening complication that may present with blood glucose levels below 250 mg/dL, a condition known as euglycemic DKA [label]. Clinicians must maintain a high index of suspicion for metabolic acidosis regardless of glycemia, especially in patients with type 1 diabetes (where the risk is markedly increased), pancreatic disorders, or those undergoing major surgery [label]. Glucosuria can persist for at least 3 days after the last dose, and DKA symptoms may last up to 2 weeks post-discontinuation in some cases [label].

Volume depletion may manifest as symptomatic hypotension or acute kidney injury (AKI), particularly in patients aged 75 years or older, those with baseline eGFR <60 mL/min/1.73 m², or those using loop diuretics [label], ^[65]A1a. In the CONFIDENCE trial, simultaneous initiation of empagliflozin and finerenone was well-tolerated and appeared to mitigate the risk of hyperkalemia often associated with renin-angiotensin system inhibitors ^[50]B2b, ^[66]A1b.

Rare and Emerging Safety Data

Necrotizing fasciitis of the perineum ( Fournier's gangrene ) has been reported in post-marketing surveillance, requiring immediate surgical intervention and permanent drug discontinuation [label]. Hypersensitivity reactions, including angioedema and urticaria, are rare but necessitate prompt cessation [label]. Beyond traditional metabolic use, recent trials in patients with schizophrenia spectrum disorders taking atypical antipsychotics demonstrated that empagliflozin 10 mg is well-tolerated and may assist in mitigating antipsychotic-induced weight gain ^[44]A1b. Furthermore, the EMPA-KIDNEY trial demonstrated that empagliflozin reduces the risk of all-cause hospitalization in patients with chronic kidney disease ^[59]A1b.

Enhanced natriuresis and osmotic diuresis occur when empagliflozin is combined with thiazide or loop diuretics , potentially precipitating symptomatic volume depletion and acute kidney injury [label]. While pharmacokinetic studies demonstrate no significant interaction between empagliflozin 25 mg and hydrochlorothiazide 25 mg or torasemide 5 mg ^[32]A1b, the clinical impact includes increased urine volume (mean increase of 341 mL on day 1) and frequency [label]. In patients with heart failure and reduced ejection fraction (HFrEF), the combination with loop diuretics may provide a therapeutic advantage by improving cardiorespiratory fitness, as evidenced by increased peak oxygen consumption ^[71]C4.

Glycemic and Metabolic Combinations

The risk of hypoglycemia increases significantly when empagliflozin is added to insulin or insulin secretagogues, such as sulfonylureas [label]. To mitigate this, clinicians should consider preemptive dose reductions of the insulin-stimulating agent [label]. Conversely, coadministration with dipeptidyl peptidase-4 (DPP-4) inhibitors like sitagliptin 50 mg ^[22]B2b or evogliptin 5 mg ^[73]A1b does not require dose adjustments, as no clinically relevant pharmacokinetic or pharmacodynamic interactions exist. Similarly, combining empagliflozin 10 mg with pioglitazone 15 mg provides synergistic benefits in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) without requiring dose modification ^{[74]A1b[31]A1b}.

Lithium and Laboratory Interference

Serum lithium concentrations may decrease during SGLT2 inhibitor therapy, likely due to increased renal lithium clearance [label]. Frequent monitoring of lithium levels is mandatory during empagliflozin initiation and titration [label]. Furthermore, the drug's mechanism of action inherently alters specific diagnostic parameters; it induces a positive urine glucose test and renders the 1,5-anhydroglucitol (1,5-AG) assay unreliable for assessing glycemic control [label]. Alternative methods, such as HbA1c, should be utilized for monitoring [label].

Hypersensitivity reactions, including angioedema and urticaria , represent absolute contraindications to treatment [label]. While the drug provides significant metabolic and cardiovascular benefits, its use is restricted in specific clinical contexts to ensure safety and avoid developmental or hemodynamic complications.

Pregnancy and Lactation

Avoidance of therapy is recommended during the second and third trimesters of pregnancy due to potential risks to fetal renal development [label]. Animal models demonstrate that exposure during periods corresponding to human renal maturation results in reversible renal pelvic and tubule dilatations at 13-times the maximum clinical dose [label]. Because human nephrogenesis continues through the first two years of postnatal life, breastfeeding is not recommended to prevent potential lactational exposure and subsequent adverse effects on the developing kidney [label].

Pediatrics

Pediatric patients aged 10 years and older with type 2 diabetes may receive an initial dose of 10 mg once daily, which may be escalated to 25 mg if HbA1c targets are not met [label]^[78]D5. The pivotal DINAMO trial demonstrated a significant reduction in HbA1c (adjusted mean difference -0.84% vs placebo) in this cohort ^[77]A1b. Pharmacokinetic modeling indicates that while maximum plasma concentrations are slightly lower in adolescents compared to adults, the overall exposure-response relationship remains consistent, supporting the use of adult-based dosing regimens ^{[27]B2b[57]A1b}.

Geriatrics

Geriatric patients, particularly those ≥75 years, face an increased risk of symptomatic hypotension and volume depletion [label]. Pooled safety data show volume depletion events occurring at 3.0–3.2 per 100 patient-years in the elderly compared to 2.3 in placebo groups ^[65]A1a. While an acute, reversible dip in eGFR of 2–4 mL/min/1.73 m² typically occurs within the first four weeks of initiation, long-term therapy is associated with a significant slowing of kidney function decline (annual slope -0.23 vs -1.46 mL/min/1.73 m² for placebo) ^[53]A1b.

Immunocompromised and Infection Risk

Patients with compromised immune status or those with chronic perineal skin conditions require vigilant monitoring for genital mycotic infections and rare but severe Fournier’s gangrene [label]. Clinical data indicate infection rates of 3.4–3.5 per 100 patient-years ^[65]A1a. Any report of perineal pain, tenderness, or erythema accompanied by fever requires immediate discontinuation and surgical evaluation [label].